(Total Views: 512)
Posted On: 09/22/2020 3:40:03 PM
Post# of 154179
Re: Goosebumps #57338
“In his interview he speculated that 10-20% of the world population will need Leronlimab.”
Speculation is only speculation. Just because leronlimab’s MOA works on paper for multiple indications doesn’t mean that it will in humans. We’ve seen this with GvHD, where either leronlimab is not working or they can’t get the dosing correct. And most of these indications, if they ever come to fruition, are 5-10 years or more in the future. I invested in 2015 because of monotherapy and it appears that 5 years later a phase 3 trial is still needed.
“This is why he always refers to production, production, production.”
He was saying this in regards to the COVID19 indication, not the 20+ other Potential indications.
Speculation is only speculation. Just because leronlimab’s MOA works on paper for multiple indications doesn’t mean that it will in humans. We’ve seen this with GvHD, where either leronlimab is not working or they can’t get the dosing correct. And most of these indications, if they ever come to fruition, are 5-10 years or more in the future. I invested in 2015 because of monotherapy and it appears that 5 years later a phase 3 trial is still needed.
“This is why he always refers to production, production, production.”
He was saying this in regards to the COVID19 indication, not the 20+ other Potential indications.
(2)
(0)
